EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid‐Turnaround Co‐Administration of mRNA‐Based MHC‐I and MHC‐II‐Restricted Neoantigens Enhances Immune Responses of Antigen‐Specific CD8 + T Cells and Anti‐Cancer Efficacy in Colorectal Cancer

Seongje Cho iD, Woori Kwak, Hyunho Yoon, Jisun Lee, Seonghyun Lee, Hyo-Jung Park, Sohee Jo, Yu-Sun Lee, Yu-Jeong Seo, Youngran Cho, Seo-Hyeon Bae, Subin Yoon und 15 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202506426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Seongje Cho und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, 14662, Republic of Korea. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Colorectal Neoplasms, Cancer Vaccines, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Personalized cancer vaccines (PCVs) represent a promising frontier in cancer immunotherapy; however, challenges in neoantigen prediction and treatment optimization persist. This study aims to introduce an innovative mRNA‐based PCV platform that addresses these limitations. Co‐administration of our major histocompatibility complex (MHC)‐I and MHC‐II‐restricted neoantigens increases antigen‐specific T cell responses and exhibits strong anti‐cancer efficacy, significantly inducing antigen‐specific CD8 + T cell‐immune responses. The mRNA‐based vaccine targeting the novel antigens demonstrates anti‐tumor efficacy in a murine model of colorectal cancer and reduces post‐surgery recurrence in mRNA‐vaccinated mice. Notably, early‐stage vaccination induces a striking anti‐cancer effect, underscoring the critical role of MHC‐II neoantigens alongside MHC‐I antigen prediction in shaping effective anti‐tumor immunity, in the activation of antigen‐specific CD8 + T cells. In addition, the combination of immune checkpoint inhibitors and the vaccine synergistically inhibits tumor growth by inducing robust T cell responses and promoting favorable alterations in the tumor microenvironment. Taken together, the results provide a strong rationale for the clinical investigation of rapid‐turnaround co‐administration of MHC‐I/II‐restricted neoantigens‐based mRNA vaccines in colorectal cancer, as supported by the anti‐tumor efficacy of early‐stage application and combination immunotherapy approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesColorectal NeoplasmsCancer VaccinesHistocompatibility Antigens Class IAntigens, NeoplasmRNA, MessengerHistocompatibility Antigens Class IIAnimalsMiceImmunotherapyMice, Inbred C57BLHumansFemale

Stichwörter der Autor:innen

colorectal cancerlipid nanoparticlemRNAneoantigenpersonalized cancer vaccinepost‐surgery recurrence

Substanzen

Cancer VaccinesHistocompatibility Antigens Class IAntigens, NeoplasmRNA, MessengerHistocompatibility Antigens Class II

Autor:innen und Institutionen

  • Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, 14662, Republic of Korea.
  • BK Four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, 14662, Republic of Korea.
  • Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, 03760, Republic of Korea.
  • Department of Biomedical Laboratory Science, Daegu Haany University, Gyeongsan, 38578, Republic of Korea.
  • SML Biopharm, Gwangmyeong, 14303, Republic of Korea.
  • Department of Molecular Genetics & Dental Pharmacology, School of Dentistry, Seoul National University, Seoul, 03080, Republic of Korea.

ORCID-Profile: Seongje Cho, Jae-Hwan Nam

Förderung

  • Ministry of Food and Drug Safety

Zitieren

APA

Cho, S., Kwak, W., Yoon, H., Lee, J., Lee, S., Park, H. J., Jo, S., Lee, Y. S., Seo, Y. J., Cho, Y., Bae, S. H., Yoon, S., Roh, G., Ha, D., Oh, A., Choi, E. J., Lee, S. Y., Choi, H., Kim, J., …, & Nam, J. H. (2025). Rapid‐Turnaround Co‐Administration of mRNA‐Based MHC‐I and MHC‐II‐Restricted Neoantigens Enhances Immune Responses of Antigen‐Specific CD8 + T Cells and Anti‐Cancer Efficacy in Colorectal Cancer. Advanced Science. https://doi.org/10.1002/advs.202506426

Vancouver

Cho S, Kwak W, Yoon H, Lee J, Lee S, Park HJ, et al. Rapid‐Turnaround Co‐Administration of mRNA‐Based MHC‐I and MHC‐II‐Restricted Neoantigens Enhances Immune Responses of Antigen‐Specific CD8 + T Cells and Anti‐Cancer Efficacy in Colorectal Cancer. Advanced Science. 2025. doi:10.1002/advs.202506426

BibTeX
@article{Cho2025,
  author = {Cho, Seongje and Kwak, Woori and Yoon, Hyunho and Lee, Jisun and Lee, Seonghyun and Park, Hyo-Jung and Jo, Sohee and Lee, Yu-Sun and Seo, Yu-Jeong and Cho, Youngran and Bae, Seo-Hyeon and Yoon, Subin and Roh, Gahyun and Ha, Dahyeon and Oh, Ayoung and Choi, Eun-Jin and Lee, Soo-Yeon and Choi, Huijeong and Kim, Jungmin and Lee, Yeeun and Lee, Sowon and Park, Sang-In and Kim, Dae-Keun and Chang, Jun and Kim, Ki Tae and Kim, Kwoneel and Nam, Jae-Hwan},
  title = {Rapid‐Turnaround Co‐Administration of mRNA‐Based MHC‐I and MHC‐II‐Restricted Neoantigens Enhances Immune Responses of Antigen‐Specific CD8 + T Cells and Anti‐Cancer Efficacy in Colorectal Cancer},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202506426}
}
Kostenlos starten →